Alexion Pharmaceuticals

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).

In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Alexion Pharmaceuticals, established in 1992 and headquartered in United States, North America., specializes in Late Stage Venture investments across Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics, Genetics, Financial Services, Finance, Asset Management, Insurance. The organization boasts a portfolio of 2 investments, with an average round size of $237.5M and 1 successful exits. Their recent investments include Moderna, Wellington Management, AstraZeneca, Invus, RA Capital Management. The highest investment round they participated in was $51.0B. Among their most notable exits are Moderna and Wellington Management. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.